摘要
收集接受硼替佐米+地塞米松+沙利度胺(BDT)方案化疗的25例多发性骨髓瘤(MM)患者的临床信息,对其疗效、相关影响因素及不良反应进行回顾性分析及评价。以硼替佐米为基础的化疗方案治疗25例MM患者的总有效(OR)率为80.00%(20/25),其中完全缓解(CR)9例(36.00%),非常好的部分缓解(VGPR)6例(24.00%),部分缓解(PR)5例(20.00%);复发/难治性MM患者与新诊断MM患者的疗效相当(OR率:62.5%vs 88.24%,P>0.05);国际分期系统(ISS)Ⅰ+Ⅱ期患者疗效与Ⅲ期患者疗效差异无统计学意义(OR率:83.33%vs 76.92%;P>0.05);长疗程(≥4个疗程)化疗组患者的CR率明显高于短疗程(3、2、1个疗程)化疗组患者(77.78%vs 30.77%vs15.79%vs 4.00%);浆细胞白血病及严重肾功能损害的MM瘤可获得VGPR以上疗效;主要不良反应包括周围神经病变、胃肠道反应、血小板减少、粒细胞缺乏、皮疹等,经过对症治疗以及调整剂量后均能改善。
The clinical features of all 25 multiple myeloma （ MM ） patients who were treated with BDT regimen （ bortezomib and dexamethasone and thalidomide） were recruited. The efficacy and related influence factors and adverse drug reactions were retrospectively evaluated. The overall remission（OR） rate was 80. 00%（20/25） and the complete remission （CR） rate was 36. 00% （9/25）,very good partial remission （VGPR） and partial remission （PR） rate were 24. 00% （6/25） and 20. 00%（5/25） respectively in MM patients with BDT regimen. The OR rate of relapsing/refractory MM patients was not statistically lower than that of newly-diagnosed MM patients （62. 5% vs 88. 24%,P〉0. 05）. The OR rate of ISSⅢstage patients was as better as that of ISS I andⅡstage patients（83. 33% vs 76. 92%, P〉0. 05）. The CR rate of the arm who received many cycle regimens（≥4 cycles） was higher than that of the arm who received 4 cycles regimens（3,2,1 cycles）,but there was no statistically significant difference. The patients with plasma cell leukemia and renal failure were treated with bortezomib based regimen and achieved PR or above. The main adverse effects were peripheral neuropathy,gastrointestinal symptoms, thrombocytopenia,neutropenia,skin rash,et al. All adverse events were diminished by using routine ways.
出处
《安徽医科大学学报》
CAS
北大核心
2014年第7期1018-1021,共4页
Acta Universitatis Medicinalis Anhui
基金
安徽省教育厅自然科学基金(编号:KJ2009A78)
关键词
多发性骨髓瘤
硼替佐米
疗效
不良反应
multiple myeloma
bortezomib
treatment outcome
adverse reaction
